Which blockbuster products could drive the CSL share price higher?

What's going on behind the scenes in the labs of CSL?

| More on:
Two lab technicians wearing white coats discuss results they see on a computer screen.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Over the last 10 years, the CSL Limited (ASX: CSL) share price has absolutely smashed the market.

During this time, the biotherapeutics giant's shares have posted an average total return of 18.58% per annum.

To put this into context, this would have turned a $10,000 investment into approximately $55,000.

Why has the CSL share price smashed the market?

Investors have been bidding the CSL share price higher over the last 10 years thanks to its consistently strong earnings growth.

There have been a few key drivers of this impressive growth. Strong demand for CSL's existing therapies, earnings accretive acquisitions, and its lucrative research and development (R&D) pipeline.

The latter is underpinned by a material investment in R&D activities each year by management. And when I say material, I mean it.

Each year, the company reinvests in the region of 11% of its sales back into R&D. This meant an investment of over US$1 billion in FY 2022.

The good news is that this investment means there are plenty of potentially lucrative products on the way that could be the next drivers of growth. But what are they?

What will drive CSL's future growth?

Late last year, Citi commented on CSL's R&D event and highlighted CSL112 as one of the most important products under development. It commented:

The R&D budget is significant at US$1.16bn in FY22 or ~11% of revenue. CSL will continue to spend ~10-11% of revenue on R&D annually. The pipeline now includes assets from recently acquired Vifor with two assets in Phase 3. Our $340 [now $350] TP includes $22.40 for the R&D portfolio (down from $23 on delays) – the main asset remains CSL112 (cardiovascular) at $20/share on which we will get Phase 3 data in Q1 CY24. Maintain Buy, $340 TP.

What is CSL112? It is a novel apolipoprotein A-I infusion therapy to potentially reduce the risk of major adverse cardiovascular events (MACE) in patients with myocardial infarction (AMI). Completion of the trial is expected by the end of the year, which means that, if all goes to plan, it may not be too long until this therapy is generating revenue for CSL.

And what a lot of revenue it could generate! Some analysts estimate that CSL112 could pull in peak sales of US$3 billion. That compares to CSL's total FY 2022 sales of approximately US$10.13 billion.

What else?

And then there's CSL312, also known as garadacimab. This upcoming product has been described as a pipeline within a product by analysts at Goldman Sachs. It explains:

CSL312 is a humanised anti-factor XIIa monoclonal antibody in development for multiple indications including as a subcutaneous therapy for HAE [hereditary angioedema], with the potential for administration every 4 weeks (vs. every 2-3 days for Haegarda). Given its early position in the coagulation cascade, there is also potential application in various other disorders (including fibrosis, cardiovascular and inflammatory indications).

Catherine Milch, CSL's Vice President R&D Immunology, thinks very highly of the product. Milch said:

Based on the data published in The Lancet, we believe garadacimab has the potential to become a transformative first-in-class therapy, providing a new option where there is significant unmet need. The development of garadacimab reflects our commitment to providing life changing medicines for patients with HAE and for the physicians who treat them.

Overall, the future looks bright for CSL and its share price. Especially when you consider that the above are just two of a large (and growing) number of products in its pipeline.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX healthcare stock is jumping 7% on US FDA approval news

This share is giving its shareholders an early Christmas present.

Read more »

A senior pharmacist talks to a customer at the counter in a shop
Healthcare Shares

Is it too late to buy Sigma shares to cash in on the Chemist Warehouse deal?

Can investors still make healthy returns with this stock?

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Why the Mesoblast share price is diving 18% after an FDA win

Investors are sending the Mesoblast share price tumbling on Friday. But why?

Read more »

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
Healthcare Shares

Mesoblast share price rockets 30% on big US FDA news

Big news is giving this biotech a huge lift on Thursday.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

Guess which ASX healthcare stock is jumping 12% on Wednesday

This shares is rocketing this morning. But why? Let's find out.

Read more »

Man holding out Australian dollar notes, symbolising dividends.
Healthcare Shares

Here is the dividend forecast to 2029 for CSL shares

Can this blue-chip giant provide healthy dividend income?

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

The best ASX 200 healthcare stocks to buy in 2025

These shares could give your portfolio a healthy boost next year according to Bell Potter.

Read more »

In the lab at work, the mature adult woman and young adult man smile as they review the results of their successful experimentation.
Healthcare Shares

ASX 300 healthcare stock lifts off on promising new results

Up 28% in a year, the ASX healthcare stock is leaping higher on Thursday.

Read more »